ClinicalTrials.gg
Active, not recruitingNCT06603142Updated Sep 19, 2024

Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

A Phase 2/3 interventional study of Febuxostat 20MG Tablets and Febuxostat 20MG Placebo in Primary Gout and Hyperuricemia, sponsored by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as active, not recruiting.
  • Registered 4 months after the study started (first participant enrolled Apr 2024, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
636
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies in Hyperuricemia with a site in China — 18 open to participants now, 21 under way, 1 of them phase 3. Hyperuricemia · China.

Planned enrollment
3rd of 47
636 · median 100
Started
2024
with 7 others
Phase 2/3
3 of 57
none open now
Primary completion
2026-04
later than 10 of 20 live
Registered
43rd of 57
by date

Among the 57 studies in Hyperuricemia with a site in China, this one is the 3rd largest by planned enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 10 of the 20 other live ones, and was the 43rd registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

18 of the 57 studies in Hyperuricemia with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hyperuricemia with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of AR882 Capsules in patients with primary gout and hyperuricemia. The main questions it aims to answer are:

What is the efficacy of AR882 Capsules in reducing serum uric acid levels in patients with primary gout and hyperuricemia?

Researchers will compare AR882 Capsules with Febuxostat Tablets to see :

Phase II: To explore the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia, aiming to determine the dosing regimen for the Phase III study Phase III: To evaluate the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia.

Participants will:

Be randomly assigned to receive either AR882 Capsules or Febuxostat Tablets. Undergo regular assessments of serum uric acid levels. Report any adverse events or side effects experienced during the study.

03

Conditions studied

  • Primary Gout
  • Hyperuricemia

Browse trials for

Keywords

  • ULT
  • Gout
  • Hyperuricemia
  • URAT1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 and ≤ 75 years of age at the time of signing the form (ICF);
  • History of gout according to the 2015 American College Rheumatology/European League Against Rheumatism (ACR/EULAR) Gout Classification Criteria,with serum urate (sUA) levels ≥480μmol/L;
  • (BMI) must be within the range of ≥ 18 to ≤ 35 kg/m2;
  • Participants with must agree to use medically accepted effective during the study period and for 3 months after the last dose
  • Willing to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to the study drug or its components, or previous intolerance or to febuxostat;
  • ≥8% within 2 weeks prior to randomization;
  • Any of the following laboratory test results within 2 weeks prior to randomization:WBC\<3.0×109/L,\<90g/L,\<80×109/L,ASTorALT>1.5×,>1.5×ULN,Scr>1.5×ULN,\<60mL/min/1.73m2;
  • Use of any other uric acid-lowering drugs or concomitant medications affecting uric acid levels (including but not limited to losartan, calcium channel blockers, fenofibrate, atorvastatin, α-glucosidase inhibitors, insulin sensitizers, DPP4 inhibitors, SGLT2 inhibitors, metformin) within 2 weeks prior to randomization, except for stable dose usage;
  • Use of aspirin \&amp;gt;100 mg/day or unstable dosage within 2 weeks prior to randomization;
  • Use of any diuretics within 2 weeks prior to randomization;
  • Use of a strong or moderate CYP2C9 inhibitor or BCRP substrate drugs (see Appendix 2) within 2 weeks prior to randomization;
  • Secondary hyperuricemia due to tumors, chronic kidney disease, hematological diseases, medications, or hereditary hyperuricemia;
  • Presence of unresolved gout attacks within 2 weeks prior to randomization;
  • Imaging or clinical manifestations (e.g., hematuria, back pain) of kidney stones or urolithiasis within 2 weeks prior to randomization;
  • Other joint lesions that may confound gouty arthritis, such as rheumatoid arthritis, septic arthritis, traumatic arthritis, psoriatic arthritis, pseudogout, systemic lupus erythematosus, or joint diseases caused by chemotherapy, radiotherapy, chronic lead poisoning, acute obstructive nephropathy, etc.;
  • within 5 years, except for basal or squamous cell carcinoma of the skin and resected cervical intraepithelial neoplasia that has been successfully treated;
  • Severe cardiovascular or cerebrovascular diseases, such as (NYHA) Class III-IV congestive heart failure, uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), interval (Fridericia\&#39;s formula) prolongation (male \&gt;450 ms, female \&gt;470 ms), myocardial infarction, acute stroke, uncontrolled arrhythmia, or unstable angina within 12 months prior to screening;
  • Unable to swallow oral medications or have gastrointestinal diseases that may interfere with drug absorption, or have active gastric or duodenal ulcers within 3 months prior to screening;
  • Systemic diseases requiring therapy, or vaccination within 2 weeks prior to randomization;
  • Other severe or uncontrolled diseases;
  • History of xanthinuria;
  • Poor compliance (e.g., alcoholism, drug abuse) that may affect the safety and efficacy evaluation of the study drug, as judged by the investigator;
  • Pregnant or breastfeeding women;
  • Any acute inflammation or active infection;
  • Active (HBsAg positive and HBV-DNA \&gt;1000 IU/mL), or positive for serum antibodies, antibodies, or syphilis antibodies;
  • Previous kidney removal and/or kidney transplantation;
  • Major surgery within 3 months prior to randomization, or planned major surgery during the study;
  • Blood donation (or blood loss) ≥400 mL or blood transfusion within 3 months prior to randomization;
  • Participation in another drug clinical trial within 3 months prior to screening or within 5 half-lives of the product (whichever is longer), or participation in a medical device clinical trial within 3 months prior to screening;
  • Any other condition deemed unsuitable for study participation by the investigator
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
636 participants (estimated)

Study arms

  • Experimental
    AR882 50MG

    Titrated from 12.5 mg to 25 mg (2 weeks each), then 50 mg for 4 weeks, with matching Febuxostat placebo.

    Drug: Febuxostat 20MG Placebo · Drug: AR882 25MG · Drug: AR882 12.5MG · Drug: Febuxostat 40MG Placebo

  • Active comparator
    Febuxostat 40MG

    Titrated from 20 mg (4 weeks) to 40 mg (4 weeks) Febuxostat, with matching AR882 placebo.

    Drug: Febuxostat 20MG Tablets · Drug: AR882 25MG Placebo · Drug: AR882 12.5MG Placebo · Drug: Febuxostat 40MG Tablets

  • Experimental
    AR882 75MG

    Titrated from 25 mg to 50 mg (2 weeks each), then 75 mg for 4 weeks, with matching Febuxostat placebo.

    Drug: Febuxostat 20MG Placebo · Drug: AR882 25MG · Drug: Febuxostat 40MG Placebo

Interventions

  • Febuxostat 20MG Tablets

  • DrugFebuxostat 20MG Placebo

    Febuxostat 20MG Placebo

  • AR882 25 MG Capsules

  • AR882 12.5 MG Capsules

  • DrugAR882 25MG Placebo

    AR882 25MG Placebo

  • DrugAR882 12.5MG Placebo

    AR882 12.5MG Placebo

  • Febuxostat 40MG Tablets

  • DrugFebuxostat 40MG Placebo

    Febuxostat 40MG Placebo

06

What researchers measure

Primary outcomes

  1. The percentage of participants with serum uric acid &lt;360 μmol/L

    Time frame: 8 Weeks

Secondary outcomes

  1. The percentage of participants with serum uric acid &lt;300, 240 μmol/L

    Time frame: 8 Weeks

  2. The percentage of participants with serum uric acid &lt;360, 300, 240 μmol/L

    Time frame: 2, 4, and 6 Weeks

  3. The absolute change in serum uric acid levels from baseline

    Time frame: 2, 4, 6, and 8 Weeks

  4. The percentage change in serum uric acid levels from baseline

    Time frame: 2, 4, 6, and 8 Weeks

  5. Serum uric acid levels

    Time frame: 2, 4, 6, and 8 Weeks

  6. Adverse events

    Time frame: 8 Weeks

07

Study locations

1 site
  • Peking Union Medical College Hospital, Chinese Academy of Medical Science
    Beijing, 100730, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Apr 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Apr 22, 2024
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06603142
Lead sponsor
Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Apr 22, 2024
Primary completion
Apr 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Sep 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AR882

Start the discussion